This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
Now that twitter has recovered from its downtime, a catch-up tweetorial on apixaban for AF in patients on dialysis for you.
Many nephrologists make decisions about which anticoagulant (if any) to recommend for atrial fibrillation in patients on haemodialysis on a weekly basis.
— Nephrology Journal Club (@NephJC) March 6, 2023
And we finally have more randomised data!
Enjoy a rapid catch-up with #TenTweetNephJC pic.twitter.com/r99aAqPeiV
